Sign In
Buy ICCM
$0.152
+0.0127 (+9.14%)
At Close: Jun 03, 2026
IceCure Medical Q4 Earnings Call Highlights
02:02am, Thursday, 19'th Mar 2026
IceCure Medical (NASDAQ: ICCM) reported record sales for the fourth quarter and full year 2025 and outlined a commercialization strategy centered on its ProSense cryoablation system following recent r
IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript
12:42pm, Tuesday, 17'th Mar 2026
IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript
IceCure Reports 2025 Full Year Financial & Operational Results
08:30am, Tuesday, 17'th Mar 2026
Record 4th quarter and full year sales of $1.3 million and $3.4 million, respectively Strong commercial momentum for ProSense® in the U.S. and globally following FDA clearance in low-risk breast canc
IceCure Medical (ICCM) Projected to Post Earnings on Tuesday
01:56am, Sunday, 15'th Mar 2026
IceCure Medical (NASDAQ: ICCM - Get Free Report) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect IceCure Medical to post earnings of ($0.04)
U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer
08:30am, Wednesday, 11'th Mar 2026
IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense® Clinical study sites may offer ProSense® cryoa
IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026
08:30am, Tuesday, 10'th Mar 2026
CAESAREA, Israel, March 10, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr
American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer
08:30am, Monday, 09'th Mar 2026
IceCure's ICE3 study and the FDA Advisory Panel's favorable vote on ProSense® cryoablation's benefit-risk profile for low-risk breast cancer played a key role in the ASBrS 2026 Resource Guide update
Treatment with ProSense® resulted in 92.9% volume reduction of fibroadenoma one-year post-cryoablation Findings may impact treatment guidelines issued by medical societies for large non-cancerous bre
Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rate Incidence of kidney cancer is growing w
First procedures to be performed in the coming weeks at Alabama's largest non-governmental healthcare system Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense�
IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®
08:30am, Wednesday, 11'th Feb 2026
ProSense® system recently received FDA marketing authorization for the treatment of low-risk breast cancer Cryoablation for breast cancer is now included in proposed medical society guidelines for th
NYSE Group Consolidated Short Interest Report
04:00pm, Tuesday, 10'th Feb 2026
NEW YORK--(BUSINESS WIRE)--NYSE today reported short interest as of the close of business on the settlement date of January 30, 2026. SETTLEMENT DATE EXCHANGE TOTAL CURRENT SHORT INTEREST TOTAL PREVIO
IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved
04:30pm, Monday, 09'th Feb 2026
Ronen Tsimerman will continue as CFO until successor is appointed CAESAREA, Israel, Feb. 9, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a
ASBrS's updated "Resource Guide on the Use of Transcutaneous and Percutaneous Ablation for the Treatment of Benign and Malignant Tumors of the Breast" is pending finalization following the end of its
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales
08:30am, Monday, 12'th Jan 2026
Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local treatment of low-risk breast cancer,
